W
We Venture Capital
We Venture Capital is the corporate venture capital arm of Werfen, a global leader in specialized diagnostics. It invests worldwide in diagnostics, digital health, and life science tools start-ups, primarily at Series A with selective Seed and Series B checks, using an evergreen fund structure and active board engagement.
SectorsDiagnostics, Digital Health, Life Science Tools
VC MapCorporate VC
Team
Louise Warme
Head of We Venture Capital
Portfolio companies 1
Open 1 as list → On map →
Funding rounds 1
Open as list →| Date | Company | Round | Amount | Lead |
|---|---|---|---|---|
| 2025-04-29 | deepull | Series C | €50M |
Columbus Venture Partners, Panakès Partners, Mérieux Equity Partners
+9 more
|
News 8
Open as list →| Published | Article |
|---|---|
| 2026-04-07 |
TriNetX Acquires Zetta Genomics Assets ↗
GenomeWeb
2026-04-07 |
| 2025-07-24 |
Singapore's Respiree closes $11.6M Series A financing round led by We Venture Capital and ClavystBio ↗
TNGlobal (Technode Global)
2025-07-24 |
| 2025-06-30 |
Portal Biotech lands NATO Innovation Fund first biotech investment ↗
Vestbee
2025-06-30 |
| 2025-01-09 |
Doctor-led Oxford Cancer Analytics closes $16-million CAD Series A to improve early lung cancer detection ↗
BetaKit
2025-01-09 |
| 2025-01-02 |
Proton Intelligence Raises $6.95M in Seed Funding ↗
FinSMEs
2025-01-02 |
| 2024-02-15 |
Capitainer Secures SEK 30 Million Investment from We Venture Capital to Expand and Innovate in Self-Sampling Solutions ↗
Cision (Capitainer AB press release)
2024-02-15 |
| 2024-02-08 |
Zetta Genomics secures additional £1.8M in seed funding for genomic data analysis platform ↗
Tech.eu
2024-02-08 |
| 2023-09-08 |
Werfen Launches Corporate VC Arm ↗
FinSMEs
2023-09-08 |